Neoadjuvant targeted therapy in renal cell carcinoma

Nature Reviews Urology

Volumn 7, Issue 7, 2010, Pages

  Iacovelli, Roberto ^a   Raimondi, Cristina ^a   Palazzo, Antonella ^a   Cortesi, Enrico ^a   Procopio, Giuseppe ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RECOMBINANT INTERFERON; SUNITINIB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE CONTROL; HUMAN; KIDNEY CARCINOMA; LETTER; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; DRUG DELIVERY SYSTEM; KIDNEY TUMOR; NOTE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY;

EID: 77954490301     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.2-c1     Document Type: Letter

References (7)

1. Ficarra, V. & Novara, G. Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma. Nat. Rev. Urol. 7, 63-64 (2010).
2. Zisman, A. et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20, 4559-4566 (2002).
3. Belldegrun, A. S. et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 113, 2457-2463 (2008).
4. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
5. Van Der Veldt, A. A. et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14, 2431-2436 (2008).
6. Van Der Veldt, A. A., Meijerink, M. R., Van den Eertwegh, A. J., Haanen, J. B. & Boven, E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br. J. Cancer 102, 803-809 (2010).
7. Thiam, R. et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann. Oncol. 21, 936-941 (2010).